Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EPS (Weighted Average and Diluted) (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.37 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 71.76% year-over-year to -$0.37; the TTM value through Mar 2026 reached -$2.1, up 59.54%, while the annual FY2025 figure was -$3.03, 42.72% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.37 in Q1 2026 for Phathom Pharmaceuticals, down from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.27 in Q4 2025 and bottomed at -$1.56 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.04, with a median of -$1.07 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 85.71% in 2024 and then surged 73.0% in 2025.
  • Phathom Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.33 in 2022, then dropped by 9.02% to -$1.45 in 2023, then skyrocketed by 31.03% to -$1.0 in 2024, then soared by 73.0% to -$0.27 in 2025, then tumbled by 37.04% to -$0.37 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.37, -$0.27, and -$0.41 for Q1 2026, Q4 2025, and Q3 2025 respectively.